Arcosa Files Definitive Proxy for $150/Share Acquisition by CRH Americas
ACA sits 78% above its 52-week low of $81.91.
Summary
Arcosa, Inc. has filed its definitive proxy statement, urging shareholders to approve the $150.00 per share all-cash acquisition by CRH Americas, Inc. at a special meeting on September 4, 2026.
Key Events · M&A and Partnerships · ACA
-
Merger Agreement Vote
Shareholders will vote on September 4, 2026, to approve the acquisition by CRH Americas, Inc. for $150.00 per share in cash.
-
Board Unanimously Recommends Approval
The Board of Directors unanimously recommends voting 'FOR' the merger agreement and related proposals, citing immediate fair value and avoidance of long-term business risk.
-
Financial Advisor Opinions
Evercore Group L.L.C. and Goldman Sachs & Co. LLC both rendered opinions that the $150.00 per share merger consideration is fair from a financial point of view to shareholders.
-
Executive Merger-Related Compensation
Named executive officers are eligible for significant 'golden parachute' payments, including accelerated equity vesting and severance, totaling over $50 million.
Analysis · ACA · Manufacturing
This definitive proxy statement provides shareholders with the final details and board recommendation for the proposed all-cash acquisition of Arcosa by CRH Americas for $150.00 per share. The board unanimously recommends approval, supported by fairness opinions from Evercore and Goldman Sachs. The transaction is expected to close in Q1 2027, subject to shareholder and regulatory approvals.
At the time of this filing, ACA was trading at $145.54 on NYSE in the Manufacturing sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $81.91 to $146.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.